bioAffinity Technologies, Inc., a biotechnology company, is engaged in the development of non-invasive diagnostic tests and specific treatments for cancer. The company is headquartered in San Antonio, Texas.
| Revenue (TTM) | $5.90M |
| Gross Profit (TTM) | $2.04M |
| EBITDA | $-11.97M |
| Operating Margin | -220.80% |
| Return on Equity | -1860.00% |
| Return on Assets | -125.10% |
| Revenue/Share (TTM) | $23.20 |
| Book Value | $8.34 |
| Price-to-Book | 0.42 |
| Price-to-Sales (TTM) | 0.56 |
| EV/Revenue | 0.0991 |
| EV/EBITDA | -0.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 19.00% |
| Shares Outstanding | $1.28M |
| Float | 504,080 |
| % Insiders | 0.76% |
| % Institutions | 4.82% |
Volatility is currently expanding
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports third quarter 2026 results, continued momentum in CyPath Lung commercialization.
JERSEY CITY, N.J., Oct. 9, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, has closed its previously announced registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) with an institutional investor at a purchase price of $6.122 (or $6.115 per pre-funded warrant), in a registered direct offering priced at-the-market under Nasdaq rules.
JERSEY CITY, N.J., Oct. 8, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, has entered into a definitive agreement with an institutional investor to sell shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $6.122 (or $6.115 per pre-funded warrant), in a registered direct offering priced at-the-market under Nasdaq rules.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies will present two posters related to the CyPath Lung diagnostic test for lung cancer at the 2026 NAVREF Annual Conference.
Shares of BioAffinity Technologies Inc. (NASDAQ:BIAF) are surging Thursday afternoon following the grant of a key Hong Kong patent for its CyPath Lung diagnostic. The rally is also boosting BioAffinity's Warrants (NASDAQ:BIAFW), up nearly 20% late Thursday.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--BIAF President and CEO Maria Zannes will present a corporate update at the H.C. Wainwright 28th Annual Global Investment Conference Sept. 14-16.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies enters distribution agreement with AvMEDICAL to expand CyPath Lung sales reach and access to government healthcare systems.
JERSEY CITY, N.J., Aug. 14, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of pre-funded warrants to purchase an aggregate of 8,462,027 shares of common stock.
JERSEY CITY, N.J., , Aug. 13, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has entered into a securities purchase agreement with an institutional investor to sell 8,462,027 shares of common stock (or pre-funded warrants in lieu thereof), together with two warrants to purchase up to an aggregate 16,924,054 shares of common stock, in a private placement offering priced at-the-market under Nasdaq rules.
bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BIAF and any ticker you trade — then tracks every position and per-strategy win rate.
